Literature DB >> 21129401

Risk factors for colistin-associated nephrotoxicity.

Pinyo Rattanaumpawan, Puangpaka Ungprasert, Visanu Thamlikitkul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21129401     DOI： 10.1016/j.jinf.2010.11.013

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  22 in total

Review 1.  A review on colistin nephrotoxicity.

Authors:  Atefeh Ordooei Javan; Shervin Shokouhi; Zahra Sahraei
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

2.  Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity.

Authors:  Rujipas Sirijatuphat; Samornrod Limmahakhun; Vorapan Sirivatanauksorn; Roger L Nation; Jian Li; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

3.  Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury.

Authors:  Todd A Miano; Ebbing Lautenbach; F Perry Wilson; Wensheng Guo; Yuliya Borovskiy; Sean Hennessy
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 8.237

4.  Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.

Authors:  Moataz M Hassan; Zied Gaifer; Ibrahim S Al-Zakwani
Journal:  Int J Clin Pharm       Date:  2018-03-14

5.  Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.

Authors:  Alan Forrest; Samira M Garonzik; Visanu Thamlikitkul; Evangelos J Giamarellos-Bourboulis; David L Paterson; Jian Li; Fernanda P Silveira; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Renal and neurological side effects of colistin in critically ill patients.

Authors:  Herbert Spapen; Rita Jacobs; Viola Van Gorp; Joris Troubleyn; Patrick M Honoré
Journal:  Ann Intensive Care       Date:  2011-05-25       Impact factor: 6.925

7.  High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.

Authors:  Lidia Dalfino; Filomena Puntillo; Adriana Mosca; Rosa Monno; Maria Luigia Spada; Sara Coppolecchia; Giuseppe Miragliotta; Francesco Bruno; Nicola Brienza
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

8.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

9.  High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.

Authors:  Ali S Omrani; Wafa A Alfahad; Mohamed M Shoukri; Abeer M Baadani; Sultan Aldalbahi; Ali A Almitwazi; Ali M Albarrak
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-01-16       Impact factor: 3.944

10.  Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.

Authors:  Luisa Sorlí; Sonia Luque; Santiago Grau; Núria Berenguer; Concepción Segura; María Milagro Montero; Francisco Alvarez-Lerma; Hernando Knobel; Natividad Benito; Juan P Horcajada
Journal:  BMC Infect Dis       Date:  2013-08-19       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.